康哲藥業（867.HK/8A8.SG）：創新藥口服JAK1抑制劑Povorcitinib在中國獲納入「突破性治療品種」
Dec 16, 2025 08:07 HKT |  |
|
康哲药业（867.HK/8A8.SG）：创新药口服JAK1抑制剂Povorcitinib在中国获纳入"突破性治疗品种"
Dec 16, 2025 08:06 HKT | |
|
CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China
Dec 15, 2025 21:00 HKT | |
|
康哲藥業（0867）抗急性缺血性卒中創新藥注射用Y-3中國NDA獲受理
Dec 11, 2025 20:01 HKT | |
|
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China
Dec 11, 2025 20:00 HKT | |
|
康哲药业（0867）抗急性缺血性卒中创新药注射用Y-3中国NDA获受理
Dec 11, 2025 19:53 HKT | |
|
君聖泰醫藥公佈HTD1801與達格列淨的頭對頭III期臨床研究結果 展現控糖優勢及心血管代謝優效獲益
Dec 02, 2025 10:59 HKT |  |
|
君圣泰医药公布HTD1801与达格列净的头对头III期临床研究结果 展现控糖优势及心血管代谢优效获益
Dec 02, 2025 10:16 HKT | |
|
OBI-902 has been granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma
Nov 17, 2025 20:00 HKT |  |
|
OBI-902获美国FDA审核通过用于治疗胆管癌的“孤儿药”资格认定
Nov 17, 2025 20:00 HKT | |
|
OBI-902 獲美國 FDA 審核通過治療膽管癌的「孤兒藥」資格認定
Nov 17, 2025 20:00 HKT | |
|
全球首创抗炎代谢调节剂HTD1801完成2型糖尿病III期临床研究 展现持续52周的综合获益与安全性优势
Oct 31, 2025 08:30 HKT | |
|
全球首創抗炎代謝調節劑HTD1801完成2型糖尿病III期臨床研究 展現持續52周的綜合獲益與安全性優勢
Oct 31, 2025 08:30 HKT | |
|
CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Ra Humanized Monoclonal Antibody Injection MG-K10 Accepted in China
Oct 30, 2025 20:00 HKT | |
|
康哲药业（867.HK;8A8.SG）长效抗IL-4Rα人源化单抗注射液MG-K10特应性皮炎适应症中国NDA已获受理
Oct 30, 2025 18:27 HKT | |
|
康哲藥業（867.HK;8A8.SG）長效抗IL-4Rα人源化單抗注射液MG-K10特應性皮炎適應症中國NDA已獲受理
Oct 30, 2025 18:27 HKT | |
|
康哲藥業（867.HK; 8A8.SG）簽訂眼科藥物諾適得(R)與倍優適(R)經銷協議
Oct 28, 2025 18:22 HKT | |
|
CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis(R) and Beovu(R)
Oct 27, 2025 22:00 HKT | |
|
康哲药业（867.HK; 8A8.SG）签订眼科药物诺适得(R)与倍优适(R)经销协议
Oct 27, 2025 18:29 HKT | |
|
Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14
Oct 14, 2025 17:38 HKT |  |
|